Search
BioMarin Pharmaceutical Inc
BMRNAdd to Watchlist
63.940USD
-1.140-1.75%
Close 09-18 16:00（ET）
12.39BMarket Cap
45.89P/E TTM
BioMarin Pharmaceutical Inc (BMRN) Stock Price Target & Forecast
Analyst Rating
Based on 27 analysts giving stock ratings to BioMarin Pharmaceutical Inc in the past month.
Buy
8 Strong Buy
13 Buy
6 Hold
0 Sell
0 Strong Sell
Target Price
91.826USD+42.48%
BMRN Analyst Recommendation Trends
In the current month, BMRN has received 13 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. BMRN average Analyst price target in the last month is 91.826.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
8
8
8
8
7
7
8
9
13
13
13
12
13
13
12
13
6
6
5
5
5
6
6
6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
27
27
26
25
25
26
26
28
BMRN Analyst Rating for Peer Comparison
Updated: Sep 18, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
7
17
12
1
0
37
Amgen Inc
AMGN
4
9
21
2
1
37
Eli Lilly and Co
LLY
10
17
6
1
0
34
AbbVie Inc
ABBV
8
19
6
0
0
33
Alnylam Pharmaceuticals Inc
ALNY
7
17
8
0
0
32
Merck & Co Inc
MRK
8
14
10
0
0
32
Pfizer Inc
PFE
5
6
19
1
1
32
Regeneron Pharmaceuticals Inc
REGN
6
15
11
0
0
32
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Vertex Pharmaceuticals Inc
VRTX
9
16
5
0
1
31
Financial Forecasting
Based on analysts' estimates, BMRN EPS is projected to reach 0.824 in FY2026Q3, following reported EPS of 0.231 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
0.62
0.75
0.69
0.82
1.24
Actual
-0.24
0.55
0.23
--
--
Surprise
-138.80%
-26.97%
-66.35%
--
--
FAQs
What is BioMarin Pharmaceutical Inc's expected revenue for the next quarter?
BioMarin Pharmaceutical Inc's expected revenue is 1.03B.
What is BioMarin Pharmaceutical Inc's price target?
Analysts forecast that BioMarin Pharmaceutical Inc's price target is USD 91.83, with the highest forecast at USD 124.00 and the lowest forecast at USD 60.00.
How have BioMarin Pharmaceutical IncBMRN's recent earnings per share performed?
The market expectation was USD 0.23, while BioMarin Pharmaceutical IncBMRN's earnings per share (EPS) for the previous quarter was USD 0.55. EPS for the next quarter is expected at USD 0.82.
What is the analyst rating for BioMarin Pharmaceutical Inc?
Based on the ratings of BioMarin Pharmaceutical Inc's stock from 27 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.